Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis (MG-Ex)

March 20, 2026 updated by: HealthPartners Institute
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Participants will be enrolled into the NeuroWell exercise program, which is geared toward individuals with neurological disorders or injuries and led by Certified Exercise Physiologists (CEPs) at the HealthPartners Neuroscience Center. A total of 20 people with MG will be enrolled in this study and participate in a small group exercise program 3 times a week for 12 weeks. Participants will be randomized into two exercise groups: 1) Light intensity or 2) Moderate intensity. We hypothesize that light and moderate intensity exercise will be feasible, acceptable, and tolerable in adults with MG and that individuals in the light intensity exercise group will be able to achieve the same improvement in health outcomes as the moderate intensity group.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Ability to provide and provision of signed and dated informed consent form.
  • Age 18-80
  • Diagnosis of generalized MG.
  • On a stable MG prescription medication regimen for the last 3 months.

Exclusion Criteria:

  • Non-English speaking
  • Regular exercise participation within the month prior to study enrollment or any outside exercise participation during the study intervention period.
  • Significant cognitive impairment of any etiology that would impact study participation.
  • History of heart failure, chronic lung disease, angina or any other condition that causes unreasonable shortness of breath on exertion.
  • History of any serious neurological, psychiatric, or substance use disorders that would impact study participation.
  • Women who are currently pregnant or planning to become pregnant during the study.
  • Any other medical conditions that could affect their ability to participate in exercise for the study duration (as determined by study investigators).
  • Active participation or past participation ≤3 months in any other interventional research study.
  • Unwilling to participate in all study related activities.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Light intensity Exercise
Aerobic intensity levels: Heart rate reserve (HRR) 30-39%, 9-11 Borg Rate of Perceived Exertion (RPE) Strength intensity levels: %One Repetition Max (1RM) 40-50%, OMNI RPE 1-4
Behavioral: Light Intensity Exercise
12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
Experimental: Moderate intensity Exercise
Aerobic intensity levels: HRR 40-59%, 12-13 Borg RPE Strength intensity levels: %1RM 60-80%, OMNI RPE 5-6
Behavioral: Moderate Intensity Exercise
12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of light and moderate intensity exercise
Time Frame: 12 weeks
Percent of participants recruited of potential participants contacted. Range: [0-100]. Higher percentage indicates higher feasibility
12 weeks
Acceptability of light and moderate intensity exercise
Time Frame: 12 weeks
Percent of participants who complete the program of participants who start the program. Range: [0-100]. Higher percentage indicates higher acceptability
12 weeks
Tolerability of light and moderate intensity exercise
Time Frame: 12 weeks
Percent of classes participants complete during the course of the program. Range: [0-100]. Higher percentage indicates higher tolerability.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular Test - 6-minute walk test
Time Frame: 12 weeks
Pre-post change in distance a person can walk during the 6-minute walk test. Change = Post distance - pre distance. Larger positive difference in distance indicates a larger improvement in cardiovascular health from pre-post program.
12 weeks
Strength Test - 1-RM Upper Limb
Time Frame: 12 weeks
Pre-post change in weight that can be lifted during the 1-RM test. Change = Post 1-RM upper limb weight -pre 1-RM upper limb weight. Larger positive difference in weight lifted indicates a larger improvement in upper limb strength from pre-post program.
12 weeks
Strength Test - 1-RM Lower Limb
Time Frame: 12 weeks
Pre-post change in weight that can be lifted during the 1-RM test. Change = Post 1-RM lower limb weight -pre 1-RM lower limb weight. Larger positive difference in weight lifted indicates a larger improvement in lower limb strength from pre-post program.
12 weeks
Cardiovascular and Strength test
Time Frame: 12 weeks
Pre-post change in time it takes a person to transfer from seated to standing position and then back to seated position 5 times. Change = Post time- pre time. Larger positive difference in time indicates a larger improvement in cardiovascular health and strength from pre-post program.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

HealthPartners Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

June 21, 2024

First Submitted That Met QC Criteria

June 30, 2024

First Posted (Actual)

July 9, 2024

Study Record Updates

Last Update Posted (Actual)

March 23, 2026

Last Update Submitted That Met QC Criteria

March 20, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A24-169

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myasthenia Gravis

Clinical Trials on Light Intensity Exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe